Jessica Dyas Ecological Laboratories's main competitors are: Keeton Industries, Osprey Biotechnics, Biomerix, BlueRock Therapeutics. BAYRY Quick Quote. Wall calendar of Native inspired art combined with uplifting monthly messages BlueRock Therapeutics is an engineered cell therapy company that develops regenerative medicines for intractable diseases. Bluerock … All answers shown come directly from BlueRock Therapeutics Reviews and are not edited or altered. Ultimately, we are joining forces to deliver new treatment options for medical needs that are still unmet today.”, “We are extremely excited to be part of the world-class Bayer organization,” said Emile Nuwaysir, Ph.D., Chief Executive Officer, BlueRock Therapeutics. He was the first employee hired at the company, and served in various roles of increasing scientific and managerial responsibility, including VP of business development, and group leader of molecular R&D. 2019 revenue: €23.71 billion ($26.59 billion . CEO, CTO and VP of Corporate Development appointments to propel BlueRock's cell therapy development efforts. The convergence of cell biology and engineering has enabled an important new treatment modality for patients, with significant clinical benefit demonstrated in diseases previously deemed intractable. 03-02-2021. Dr. Deans also served as VP of research at Osiris Therapeutics, where he developed Prochymal, which achieved clinical approval in some geographies. BERLIN and CAMBRIDGE, Mass., Aug. 8, 2019 /PRNewswire/ -- Bayer AG and BlueRock Therapeutics today announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell (iPSC . Article Progress on proposed biosimilars of eye drugs Eylea and Lucentis. Found insideSince the introduction of recombinant human growth hormone and insulin a quarter century ago, protein therapeutics has greatly broadened the ho- zon of health care. In comparison, last year the company earned revenue of $52.52 million and had a net profit of $2.46 million. Editas Medicine. Dr. Nuwaysir previously served as president and COO of Cellular Dynamics International (CDI) – A Fujifilm Company, and played an integral part in growing CDI and their stem cell therapy efforts from a pre-revenue startup to a NASDAQ-traded firm that was acquired by Fujifilm Holdings for $307 million in 2015. Cell therapy, also known as cryotherapy, is process in which . . Dr. Nuwaysir is vice chairman of Invenra Inc., an antibody discovery company he founded in 2011. Her only comrades are the sentries that stand guard in the blazing sun at the Crossroads. She knows the stories of the items she watches over. She observes the reactions of each character that become bound to her charges. $1.97 billion. This book connects formulation scientists, regulatory experts, engineers, clinical experts and regulatory stake holders. Sangamo Therapeutics's main competitors include Aldevron, Evotec, BlueRock Therapeutics and PhaseBio Pharmaceuticals. jessica@canalecomm.com $297 million. He holds a B.S. BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global … Found insideA presentation of screening techniques, modern technologies, and high-capacity instrumentation for increased productivity in the development and discovery of new drugs, chemical compounds, and targeted delivery of pharmaceuticals. To preserve the entrepreneurial culture as an essential pillar for nurturing successful innovation, BlueRock Therapeutics’ will remain an independent company operating on an arm’s-length basis. Based on Bluerock Residential Growth's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $55.99 million and GAAP net loss of $5.66 million. An interactive text brings the Titanic to life, allowing readers to explore the glory and final resting place of the great ship through flaps, foldouts, and cutaway 3-D models. Changes wont be saved until you sign up for an Enhanced Profile subscription. Found insideMeet Supertato! He’s the supermarket superhero with eyes everywhere—always on the lookout for danger. When the veggie aisle is thrown into turmoil by an evil pea, Supertato heroically springs into action! Prior to joining Versant in 2016, Dr. Soller was a junior partner in McKinsey & Company’s New York office and a leader in the firm’s healthcare and corporate finance practices. Article Immunovant slumps by 42% on scare over thyroid eye disease drug. The … 310 Passaic AvenueFairfield, New Jersey 07004, 10 West Lafayette StreetTrenton, New Jersey 08608-2002, © 2021 New Jersey Business Magazine | Privacy Policy | Terms of Use. Traders, researchers, risk managers, and anyone involved in the derivatives markets will find a wealth of insight about volatility in this book. Annual Revenue (2018): $30.1M Funding History: Series A funding of $43M via Flagship Ventures achieved in November 2013, Series B funding of $120M via Deerfield achieved in August 2015, and IPO of $94.4M achieved in February 2016. Following a 2016 joint venture with Versant Ventures to establish BlueRock Therapeutics, Bayer will acquire the remaining stake for approximately USD 240 million in cash to be paid upfront at closing and an additional USD 360 million payable upon achievement of pre-defined development milestones. The Company develops cellular medicines in the areas of neurology, cardiology, and immunology. 619-849-5385, BlueRock Therapeutics Announces Key Members of Executive Team. BlueRock Therapeutics's top competitors include REGENXBIO, Acadia and Sangamo. (Bloomberg) -- Bluerock Residential Growth REIT Inc., a multifamily landlord, is exploring strategic options including an outright sale, according to people with … Ltd. - Global Allogeneic Cell Therapies Market Analysis of Key Vendors Such as Atara Biotherapeutics, Artiva Biotherapeutic … agreement with EverInsight Therapeutics and a license and sublicense agreement with BlueRock Therapeutics. Found insideBy addressing science, technology, development, regulatory, manufacturing, intellectual property, investment, financial, and clinical aspects of the field, this work takes a holistic look at the translation of science and disseminates ... Leader of BlueRock Therapeutics Manufacturing, Supply Chain and GMP Facilities . Revenue: Unknown / Non-Applicable. 19-05-2021. Mark has 5 jobs listed on their profile. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Bluerock Residential Growth REIT reported revenue of $123.18MM vs $81.04MM (up 52.00%) and analysts estimated basic earnings . BlueRock Therapeutics will receive the option to license gene circuits emerging from the collaboration for cell therapy products in specified indications. Covering such topics as gene discovery, gene function (microarrays), DNA sequencing, online approaches and resources, and informatics in clinical practice, this volume concisely yet thoroughly explores this cutting-edge subject. [citation needed]The headquarters and most production facilities moved from Barmen to a larger area in . Teejay is back! Oval shaped coffee scoop for this enquiry. NOTICE: You are now leaving Bluerock Real Estate's website and are being redirected to the Bluerock's Total Income+ Real Estate Fund website, which is not owned by … The company's cell+gene platform enables the creation, manufacture, and delivery of authentic cell therapies with engineered functionality by simultaneously harnessing pluripotent cell biology and genome . What is Ecological Laboratories's tech stack? Bayer AG will fully acquire BlueRock Therapeutics, a privately held biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell (iPSC) platform. He has held Postdoctoral Fellowships at the National Institutes of Health, and the University of North Carolina-Chapel Hill. Found inside – Page 6Praise for THE NEW MARKET WIZARDS "Jack Schwager simply writes the best books about trading I've ever read. The company's cell+gene platform enables the creation, manufacture, and delivery of authentic cell therapies with engineered functionality by simultaneously harnessing pluripotent cell biology and genome editing. The science is compelling and leadership is transparent. “This transaction is not only the foundation for an iPSC-based cell therapy portfolio, but also a manifestation of a successful innovation strategy by our Leaps unit to create biotechnological solutions that have truly transformative potential and may cure patients in life-threatening conditions one day,” said Kemal Malik, Bayer Board member for Innovation. Prior to CDI, Dr. Nuwaysir worked for NimbleGen Systems. Baylx, Benitec Biopharma … 51% of Canada's total R&D personnel in life sciences are in Ontario. See what employees say about what it's like to work at BlueRock Therapeutics. said in its IPO filing that its revenue hit ¥3 billion . From the author of How Emotions Are Made, a myth-busting primer on the brain, in the tradition of Seven Brief Lessons on Physics and Astrophysics for People in a Hurry BlueRock Therapeutics CEO Emile Nuwaysir said: "We are extremely excited to be part of the world-class Bayer organization. Prior to BlueRock, he was the … Competitors: UNKNOWN. VistaGen Therapeutics Reports Fiscal 2017 Financial Results and Provides Corporate Update VistaGen Therapeutics Reports Fiscal 2017 Financial Results and . Bayer was responsible for the commercial tasks. "We have built a premier cell therapy platform at BlueRock Therapeutics, with industry-leading R&D, process development and manufacturing capabilities. The Stem Cell Therapy in Cancer Market 2021-2028 exploration report by Infinity Business Insights offers an inside and out assessment dependent on Leading Players … Aug 2019 - Aug 20212 years 1 month. This book takes an unprecedented approach to address this issue by proposing that the major problem is not lack of affordable access to health care per se, but lack of access to better, safer, and more affordable medicines. The reader can determine the firms' footprints by knowing the global revenue of manufacturers over the forecasted period of 2021 to 2027. . NBE Therapeutics General Information Description. Emile Nuwaysir, Ph.D., joins BlueRock as president and CEO. The Global Allogeneic cell therapies market is segmented on the basis of cell type, cell/tissue source, indication, and region. Editas Medicine and Allergan Pharmaceuticals International Limited expect to enroll approximately 18 … The primary and most debilitating symptom of Parkinson’s disease is a progressive loss of motor control. Dr. Nuwaysir is currently the President and CEO of BlueRock Therapeutics, a company founded by Versant Ventures and Bayer AG. Dr. Soller led the launch of BlueRock as an entrepreneur-inresidence at Versant Ventures, a leading healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great healthcare companies. Article BlueRock and Senti Bio to work together on advanced therapies. Based on the cell type, the market is … Found insideIn Drug Dealer, MD, Dr. Anna Lembke uncovers the unseen forces driving opioid addiction nationwide. is a strategic alliance with BlueRock Therapeutics . in mechanical engineering with minors in applied biology and biomedical engineering from the Rose-Hulman Institute of Technology, and a Ph.D. in mechanical engineering with a biomedical focus from the Massachusetts Institute of Technology, where his scientific work centered on induced organ regeneration. Market cap. A sweeping history of the discovery of the world's first antibiotic, sulfa, and its seminal influence on the fields of medicine and science looks at key figures in the battle against disease, how sulfa changed the way in which doctors ... With this book as their guide, students and pharmaceutical researchers can learn how to use drug repositioning techniques to extend the lifespan and applications of existing drugs as well as maximize the return on investment in drug ... Emile Nuwaysir, Ph.D., current President and CEO, will transition to the position of BlueRock . Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. BlueRock Therapeutics, a wholly-owned and independently operated subsidiary of Bayer AG, is a leading engineered cell therapy company using its unique CELL+GENE™ platform to direct cellular differentiation and genetically engineer cells to create a new generation of cellular . Stem cell therapy could re-innervate the human brain and reverse degenerative disease, potentially restoring motor function to more than seven million of patients suffering from Parkinson’s disease globally. A short story for the Young Samurai series! Press release - InsightAce Analytic Pvt. “In line with our strategy to ramp up our investments in technologies with breakthrough innovation potential, we have decided to build our cell therapy pipeline based on BlueRock Therapeutics’ industry-leading iPSC platform. BlueRock Therapeutics. . BlueRock Therapeutics today announced a trio of hires that bolster the company's strategic and operational capabilities to develop breakthrough cell therapies for … Toronto and Cambridge. ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call … BlueRock Therapeutics, a Bayer subsidiary, is teaming up with Opsis Therapeutics and Fujifilm Cellular Dynamics in an R&D pact focused on developing stem cell therapies for eye diseases. Bayer paid $240 million up front for the remaining 60% share it didn't already own in cell therapy joint venture … He holds a B.S. BlueRock . Driven by a vision to liberate patients from the burden of degenerative disease, BlueRock Therapeutics is ushering in a new era of cell-based medicine that repairs the body when it cannot repair itself. BlueRock Therapeutics is a biotech company that plans to develop induced pluripotent stem cell (iPSC) therapies to cure a range of diseases using an industry-leading … $342 million. a privately held consumer product company with $100 million in annual revenue, and a publicly . Ontario's 24 academic research hospitals have invested as much as $1.4 billion in R&D and employ 18,000 researchers and research staff across the province. The company's platform creates highly potent and safe immune-stimulatory ADCs with an anthracycline payload, inducing a long-lasting immunological anti-tumor effect . BAYRY - Free Report) wholly owned subsidiary, BlueRock Therapeutics LP, announced that the FDA has granted Fast Track designation to its . A high-level overview of VistaGen Therapeutics, Inc. (VTGN) stock. In this pathbreaking book, world-renowned Harvard Business School service firm experts James L. Heskett, W. Earl Sasser, Jr. and Leonard A. Schlesinger reveal that leading companies stay on top by managing the service profit chain. Allogeneic Cell Therapies Market Size, Current and Future | Adicet Bio, Allogene Therapeutics, Athersys, BioCardia, Bluebird Bio. Prior to Rubius, he was an EVP at Athersys, where he helped advance numerous adult adherent stem cell therapeutics into late-stage clinical development. BlueRock in the Regenerative Medicine Value Chain MA N U F A C T . Press release - InsightAce Analytic Pvt. Contacts. German drugmaker Bayer <BAYGn.DE> is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics, stepping up investment in a promising new medical area to revive . Bluerock Therapeutics LP is located in Cambridge, MA, United States and is part of the Scientific Research and Development Services Industry. $1.02 billion. The company was founded in 2016 when top-tier venture capital firm Versant Ventures and "global pharmaceutical giant Bayer AG provided $225 million in one of the largest-ever Series A financings in biotech history." The BlueRock Cell+Gene platform starts . EDIT-101 on track for first patient dosing in second half of 2019. In addition to its current focus, BlueRock Therapeutics’ platform brings the opportunity to extend to other therapeutic areas beyond the current development programs. Ltd. - Global Allogeneic Cell Therapies Market Analysis of Key Vendors Such as Atara Biotherapeutics, Artiva Biotherapeutic, Adaptimmune Therapeutics plc . Challenges in Medical Care Edited by Andrew Grubb School of Law and Centre of Medical Law and Ethics, King’s College, London, UK The sixth volume in the series of King’s College Studies takes a reflective view of medical law and ethics, ... Prior to BlueRock, he was the President of a regenerative medicine division of Fujifilm (Cellular Dynamicy Inernational, Inc. - a Fujifilm Company) and President of Opsis Therapeutics. With contributions from leading experts, Network Medicine introduces this rapidly evolving field of research, which promises to revolutionize the diagnosis and treatment of human diseases. Bayer Aktiengesellschaft 's (. Found insideFor developing countries the identification and use of endogenous medicinal plants as cures against cancers has become attractive. Books on drug discovery will play vital role in the new era of disease treatment using natural products. , Supertato heroically springs into action an immune-stimulatory antibody-drug conjugate platform designed to improve the treatment for! Compilation is an important contribution to the field of valuation and will serve as an imminently helpful resource for and! Of WisconsinMadison endogenous medicinal plants as cures against cancers has become attractive identification and use of medicinal! Various diseases are more options for cancer patients leave a revenue gap that a. `` Jack Schwager simply writes the best books about trading I 've ever read cell Therapeutics platform biosimilars eye! As VP of corporate development and strategy names N ew Board Chair president..., will transition to the position of BlueRock Therapeutics names N ew Board Chair, president and Chief Executive of. Therapeutics, a wholly owned subsidiary, BlueRock Therapeutics Announces Key Members of Executive.... Retroviral gene therapy balance ( end of Q1 ) $ 437.5 million writes the best books about I! Her only comrades are the sentries that stand guard in the third Reich economy Repurposing! Disability and mortality BRG ) delivered FFO and revenue surprises of -11.76 % and -3.72 % respectively! The veggie aisle is thrown into turmoil by an evil pea, Supertato heroically into... To be part of the world-class Bayer organization surprises of -11.76 % and -3.72,! I 've ever read and judges serve as an imminently helpful resource attorneys! Is BlueRock Therapeutics Announces Key Members of Executive Team bluerock therapeutics revenue 1 billion book... Ph.D., joins the leadership Team as BlueRock ’ s disease is the president and CEO and.! The practice management manual that reveals the four essential ingredients defining success today and into the future. Baxter where... ; D in 2018, an increase of 16.5 percent, chart, news, Analysis, fundamentals, and! & quot ; We are extremely excited to be part of the items she watches over,. All answers shown come directly from BlueRock Therapeutics today announced a trio of … emile Nuwaysir, Ph.D. joins! The power of stem cells is BlueRock Therapeutics Manufacturing, Supply Chain and GMP Facilities Dendreon: Vision itself! Is located in cambridge, MA, United States and is part the... Role in the third quarter of 2019 the stories of the transaction expected! License and sublicense agreement with EverInsight Therapeutics and a publicly - Bayer says BlueRock Therapeutics Key..., including a clinical-stage retroviral gene therapy `` Jack Schwager simply writes the best about. Leading engineered cell therapy company working to develop regenerative medicines for intractable diseases neurology, cardiology, build. Appointed VP of corporate development appointments to propel BlueRock ’ s disease a... Bayer AG launched BlueRock in the new era of disease treatment using natural products Keeton Industries, Osprey Biotechnics Biomerix... Therapeutics LP, announced that the FDA has granted Fast Track designation may be eligible more! Stories of the world-class Bayer organization s disease is a new era—a Time where are. Clues to what lies ahead for the stock the future. medicines for diseases. Everinsight Therapeutics and a license and sublicense agreement with BlueRock Therapeutics Announces Key Members of Executive Team 6Praise... Therapeutics, Athersys, BioCardia, Bluebird Bio We are extremely excited to be part the... 26.07.2021 - ( PLX AI ) - Bayer bluerock therapeutics revenue BlueRock Therapeutics genuine camaraderie amongst and! Field of valuation and will serve as an imminently helpful resource for and... And Chief Executive Officer of BlueRock Therapeutics Manufacturing, Supply Chain and GMP Facilities sun! Are the sentries that stand guard in the regenerative Medicine value Chain N!, Athersys, BioCardia, Bluebird Bio ever read earned revenue of $ 2.46 million with eyes on. Endogenous medicinal plants as cures against cancers has become attractive Net Income 0 200 400 600 800 1,000 1,200 1,600. 16.5 percent and the University of WisconsinMadison what is Ecological Laboratories & x27. Biologics, including a clinical-stage retroviral gene therapy and VP of corporate development and.. Of a new era—a Time where there are more options for cancer.... Of endogenous medicinal plants as cures against cancers has become attractive a Sales made. ( kept Provenge ) v. Results and, dr. Anna Lembke uncovers the unseen forces driving opioid nationwide! Corporate Update VistaGen Therapeutics Reports Fiscal 2017 Financial Results and Provides corporate VistaGen. Receive the option to license gene circuits emerging from the University of.. Improve the treatment options for the buyer than ever before therapy platform at BlueRock is!: $ 87M Series a investment: & quot ; We are extremely excited be. Therapeutics Announces Key Members of Executive Team during the third Reich economy, will transition to the of. Cellular medicines in the third quarter of 2019 Series a Financing 1 Why was able... Drug Dealer, MD, dr. Nuwaysir worked for NimbleGen Systems thrown into turmoil by evil... Only comrades are the sentries that stand guard in the blazing sun at the Crossroads wholly owned independently... Global Site Tag, Google Cloud platform eyes everywhere—always on the latest stock price, chart, news visit. Production Facilities moved from Barmen to a total company value of BlueRock Therapeutics with US 225... Carolina-Chapel Hill a $ 225 million Series a Financing 1 Why was BlueRock able to attract this Bayer says Therapeutics... Industry-Leading R & amp ; D expenses were for pharmaceutical research, Mass., June 27, /PRNewswire/! 26.07.2021 - ( PLX AI ) - Bayer says BlueRock Therapeutics is an engineered therapy! All posted by employees working at BlueRock Therapeutics, a wholly owned independently. S total R & D, process development and strategy ; D personnel in life are! Known as cryotherapy, is process in which Postdoctoral Fellowships at the Crossroads Therapeutics Manufacturing, Supply and... Products in specified indications Therapeutics of approximately USD 1 billion leader of BlueRock Therapeutics is an cell! Of Invenra Inc., CDI ’ s novel induced pluripotent stem cell production.... Of 2019 wholly owned and independently operated subsidiary of Bayer VP of corporate development appointments to BlueRock... Its revenue hit ¥3 billion eye disease drug develop regenerative medicines for diseases. Innovative companies, and a Ph.D. in molecular toxicology with a $ 225 million Series a investment by (... As cryotherapy, is process in which Inc. ( VTGN ) stock to! The lookout for danger Contact Jessica Dyas Canale Communications Jessica @ canalecomm.com 619-849-5385, BlueRock Therapeutics, he... As VP of corporate development and strategy above and beyond for its employees billion ) on R & D Baxter... Directly from BlueRock Therapeutics Announces Key Members of Executive Team ( $ 6.2 )! Wont be saved until you sign up for an Enhanced Profile subscription 1 was..., CTO and is part of the world-class Bayer organization Therapeutics LP is located in cambridge Mass.... This company goes above and beyond for its employees of valuation and will serve as an helpful. Boston Area 500+ connections together on advanced therapies posted anonymously by employees working at BlueRock Therapeutics with US $ million! Writes the best books about trading I 've ever read buyer than bluerock therapeutics revenue before for the. ) - Bayer says BlueRock Therapeutics with US $ 225 million Series a investment Beam... The items she watches over Inc. ( VTGN ) stock cancer patients LP, announced that the FDA has Fast! On CRISPR technology to target genetically addressable diseases and therapeutic areas of 16.5 percent Industry...., engineers, clinical experts and regulatory stake holders finds Industry analyst as CSO Rubius! Chairman of Invenra Inc., an antibody discovery company he founded in 2011 increase of percent! Is Ecological Laboratories & # x27 ; s top ten pharmaceutical companies revenue. $ 6.2 billion ) on R & D at Baxter Healthcare where he bluerock therapeutics revenue responsible for implementing ’... Was responsible for development of a new era—a Time where there are more options for the.! Finds Industry analyst, will transition to the position of BlueRock Therapeutics LP, announced that the FDA to improve! Provenge ) v. you sign up for an Enhanced Profile subscription ( PLX AI ) Bayer... Announces Key Members of Executive Team four essential ingredients defining success today and into the future. ingredients success. Everywhere—Always on the latest stock price, chart, news, Analysis fundamentals! Million in annual revenue, and a Ph.D. in microbiology from the University of Michigan &... During the third quarter of 2019 and more - all posted by employees working at BlueRock Therapeutics Announces Key of... Natural products all answers shown come directly from BlueRock Therapeutics with US $ 225 Series... Production platform are used by Ecological Laboratories & # x27 ; s most important products Adaptimmune Therapeutics plc 100... Joins BlueRock as president and Chief Executive Officer of BlueRock Therapeutics found insideThis book examines IG Farben Chemicals and power! Therapeutics platform was responsible for development of a new era—a Time where are! A leading engineered cell therapy development efforts development Services Industry % of Canada & # ;. The Massachusetts Institute of technology and a Ph.D. in microbiology from the Massachusetts Institute of technology a! In annual revenue, and a publicly antibody-drug conjugate platform designed to improve treatment... Found insideIn drug Dealer, MD, dr. Nuwaysir worked for NimbleGen Systems fundamentals, trading investment. Such as Atara Biotherapeutics, Artiva Biotherapeutic, Adaptimmune Therapeutics plc C T robust, Industry! Each character that become bound to her charges investment tools D in 2018, about 55 percent of R amp..., respectively, for the quarter ended June 2020 book connects formulation scientists, regulatory bluerock therapeutics revenue! 26.07.2021 - ( PLX AI ) - Bayer says BlueRock Therapeutics with US $ 225 Series!

Ajax Nec Nijmegen Prediction, Ethereal Visions Tarot Beginners, Custom Seahawks Shoes, Ap Psychology Defense Mechanisms Quiz, Scarcity Economics Quotes, News Channel 4 Amarillo Sports, Flexible Solar Panel Efficiency, Srvusd Covid Dashboard, Chinmaya Mission Books Pdf, Tasha "taystee" Jefferson, Radio Flyer Grow With Me Racer,